Matches in SemOpenAlex for { <https://semopenalex.org/work/W180806650> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W180806650 endingPage "606" @default.
- W180806650 startingPage "606" @default.
- W180806650 abstract "606 Background: Neoadjuvant chemotherapy is currently the standard of care for the management of locally advanced breast cancer, as it improves both disease-free and overall survival. Methods: Patients with histologic confirmation of locally advanced breast cancer, age >18 years, left ventricular ejection fraction >50%, good performance status and adequate bone marrow, negative chest and abdominal CT scan, renal and hepatic function were included in the study. Prior systemic therapy and radiotherapy and the presence of metastases were not allowed. The treatment schedule was as follows: GC: 1,250 mg/m2 (day 1); GC 1,000 mg/m2 plus TT 75 mg/m2 plus DX 30 mg/m2 (day 8). Pegfilgrastim was routinely administered as primary prophylaxis against febrile neutropenia. Courses were repeated each 21 days for 4–6 cycles. This study was aimed to assess the activity of GC, DX and TT in locally advanced breast cancer. Results: Fifty patients were enrolled and treated. Median age was 51 years (range: 34–73), 27 (54%) being postmenopausal patients. Infiltrating ductal carcinoma was diagnosed in 84% of cases. Tumor size was as follows: T1 (n=2, 4%), T2 (n= 31, 62%), T3 (n=14, 28%), T4 (n=2, 4%). G3 grading was found in 28% of cases. Median tumor size was 4 cm (range: 2–10). Tumors were ER+, PR+ and c-Erb-B2+ in 34 (68%), 31(62%) and 27 (54%) cases, respectively. Surgery was performed in 47 (94%) patients: 12 (26%) pathologic complete response, 24 (51%) partial response and 9 (19%) stable disease were observed resulting in a pathologic overall response rate of 77%. Logistic regression analysis revealed that larger tumor size, Mib1 higher expression and higher number of cycles were independently associated with better tumor response rates. Conclusions: This combination chemotherapy can yield a high tumor response rate. Correlation analysis suggests that this neoadjuvant regimen might be more effective in patients with larger tumors expressing Mib1, particularly if full treatment can be administered. No significant financial relationships to disclose." @default.
- W180806650 created "2016-06-24" @default.
- W180806650 creator A5009562018 @default.
- W180806650 creator A5011959585 @default.
- W180806650 creator A5015148282 @default.
- W180806650 creator A5030225853 @default.
- W180806650 creator A5033136753 @default.
- W180806650 creator A5055989726 @default.
- W180806650 creator A5062223253 @default.
- W180806650 creator A5068032424 @default.
- W180806650 creator A5088550918 @default.
- W180806650 date "2008-05-20" @default.
- W180806650 modified "2023-09-27" @default.
- W180806650 title "Phase II study of neoadjuvant gemcitabine (GC), pegylated liposomal doxorubicin (DX) and docetaxel (TT) in locally advanced breast cancer" @default.
- W180806650 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.606" @default.
- W180806650 hasPublicationYear "2008" @default.
- W180806650 type Work @default.
- W180806650 sameAs 180806650 @default.
- W180806650 citedByCount "0" @default.
- W180806650 crossrefType "journal-article" @default.
- W180806650 hasAuthorship W180806650A5009562018 @default.
- W180806650 hasAuthorship W180806650A5011959585 @default.
- W180806650 hasAuthorship W180806650A5015148282 @default.
- W180806650 hasAuthorship W180806650A5030225853 @default.
- W180806650 hasAuthorship W180806650A5033136753 @default.
- W180806650 hasAuthorship W180806650A5055989726 @default.
- W180806650 hasAuthorship W180806650A5062223253 @default.
- W180806650 hasAuthorship W180806650A5068032424 @default.
- W180806650 hasAuthorship W180806650A5088550918 @default.
- W180806650 hasConcept C121608353 @default.
- W180806650 hasConcept C126322002 @default.
- W180806650 hasConcept C126894567 @default.
- W180806650 hasConcept C141071460 @default.
- W180806650 hasConcept C143998085 @default.
- W180806650 hasConcept C2775930923 @default.
- W180806650 hasConcept C2776694085 @default.
- W180806650 hasConcept C2777063308 @default.
- W180806650 hasConcept C2778850193 @default.
- W180806650 hasConcept C2780258809 @default.
- W180806650 hasConcept C2781190966 @default.
- W180806650 hasConcept C530470458 @default.
- W180806650 hasConcept C71924100 @default.
- W180806650 hasConcept C90924648 @default.
- W180806650 hasConceptScore W180806650C121608353 @default.
- W180806650 hasConceptScore W180806650C126322002 @default.
- W180806650 hasConceptScore W180806650C126894567 @default.
- W180806650 hasConceptScore W180806650C141071460 @default.
- W180806650 hasConceptScore W180806650C143998085 @default.
- W180806650 hasConceptScore W180806650C2775930923 @default.
- W180806650 hasConceptScore W180806650C2776694085 @default.
- W180806650 hasConceptScore W180806650C2777063308 @default.
- W180806650 hasConceptScore W180806650C2778850193 @default.
- W180806650 hasConceptScore W180806650C2780258809 @default.
- W180806650 hasConceptScore W180806650C2781190966 @default.
- W180806650 hasConceptScore W180806650C530470458 @default.
- W180806650 hasConceptScore W180806650C71924100 @default.
- W180806650 hasConceptScore W180806650C90924648 @default.
- W180806650 hasIssue "15_suppl" @default.
- W180806650 hasLocation W1808066501 @default.
- W180806650 hasOpenAccess W180806650 @default.
- W180806650 hasPrimaryLocation W1808066501 @default.
- W180806650 hasRelatedWork W1968954703 @default.
- W180806650 hasRelatedWork W1973241390 @default.
- W180806650 hasRelatedWork W1987606751 @default.
- W180806650 hasRelatedWork W2003291927 @default.
- W180806650 hasRelatedWork W2004842027 @default.
- W180806650 hasRelatedWork W2033432675 @default.
- W180806650 hasRelatedWork W2058507625 @default.
- W180806650 hasRelatedWork W2078598604 @default.
- W180806650 hasRelatedWork W2129979963 @default.
- W180806650 hasRelatedWork W25071997 @default.
- W180806650 hasVolume "26" @default.
- W180806650 isParatext "false" @default.
- W180806650 isRetracted "false" @default.
- W180806650 magId "180806650" @default.
- W180806650 workType "article" @default.